Similar articles

• Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban.

  Moore KT, Plotnikov AN, Thyssen A, Vaccaro N, Ariyawansa J, Burton PB. Moore KT, et al. J Cardiovasc Pharmacol. 2011 Dec;58(6):581-8. doi: 10.1097/FJC.0b013e31822f6c2b. J Cardiovasc Pharmacol. 2011. PMID: 21822144 Clinical Trial.
• Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treated patients with atrial fibrillation? A pilot study.

  Bolek T, Samoš M, Škorňová I, Stančiaková L, Staško J, Korpallová B, Galajda P, Kubisz P, Mokáň M. Bolek T, et al. J Thromb Thrombolysis. 2019 Jan;47(1):140-145. doi: 10.1007/s11239-018-1748-5. J Thromb Thrombolysis. 2019. PMID: 30288664
• Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

  Cheng JW, Barillari G. Cheng JW, et al. J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3. J Clin Pharm Ther. 2014. PMID: 24383983 Review.
• Development of an UHPLC-UV-Method for Quantification of Direct Oral Anticoagulants: Apixaban, Rivaroxaban, Dabigatran, and its Prodrug Dabigatran Etexilate in Human Serum.

  Boehr S, Haen E. Boehr S, et al. Ther Drug Monit. 2017 Feb;39(1):66-76. doi: 10.1097/FTD.0000000000000355. Ther Drug Monit. 2017. PMID: 27861316
• Use of direct oral anticoagulants with regional anesthesia in orthopedic patients.

  Cappelleri G, Fanelli A. Cappelleri G, et al. J Clin Anesth. 2016 Aug;32:224-35. doi: 10.1016/j.jclinane.2016.02.028. Epub 2016 Apr 22. J Clin Anesth. 2016. PMID: 27290980 Review.